Canaccord said the the CRL news issued by the FDA on relacorilants NDA reinforces what they already assumed; that their model assumes another trial needs to be conducted, and they had included a three-year delay in relacorilant coming to market for Cushing’s. Canaccord maintains it Buy rating and $100 price target on Corcept Therapeutics (CORT) shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept falls as FDA reveals it warned of CRL rejection for relacorilant
- Corcept Therapeutics call volume above normal and directionally bullish
- Corcept’s TRIDENT Trial: Early Oncology Bet in Metastatic Pancreatic Cancer
- Corcept’s Nenocorilant Combo Study Moves Forward, Expanding Its Oncology Ambitions
- Corcept Therapeutics put volume heavy and directionally bearish